Rapid IO Signature Development
IO 360™ Panel
Faster than qPCR. Simpler than NGS.
Expertly Curated. Ready to Use.
New Cell Press Supplement
Pathological Mechanisms of Neurodegeneration
Small Sample. Big Insight.
nCounter® Analysis System
More insights from
Prosigna® Breast Cancer Prognostic Gene Signature Assay
Empowering personalized treatment decisions
Learn More *See product pages for regulatory status information
on actionable answers
Sergio Rutella, M.D., Ph.D., FRCPath is a Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre at Nottingham Trent University. His research focuses on acute myeloid leukemia (AML), an aggressive form of cancer that originates in the bone marrow. We recently spoke with Dr. Rutella about his research and the challenges of studying this disease.
Robin Lynn White
December 14, 2017
nCounter® Analysis in Complex Biology:
Gene expression profile predicts response to pembrolizumab
A video review of JCI publication by Ayers, et al:
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Digital Detection of Sarcoma Fusion Genes - JAN 17, 2018 9:00 AM PST
Tony Ng MD, PhD, FRCPC, Consultant Pathologist BCCA and Vancouver General Hospital
Digital detection of nucleic acids is rapidly empowering molecular characterization of challenging diseases such as non-small cell lung cancer and sarcoma. With its high specificity and reproducibility, the NanoString platform is capable of measuring RNA and DNA counts from highly degraded samples using only 150ng of FFPE-extracted RNA and only 5ng of DNA for quantitations of interest. This session will explore how groups working to analyze blood-based mRNA signatures have achieved success on the NanoString nCounter® platform.
Matt Goddeeris, Principal Scientist, Mitobridge
Mitobridge has used NanoString PlexSet Reagents for gene expression, systematically interrogating disease-related changes in mitochondrial activity and translating unique insights into potential new treatments.
Deciphering the Complexity of the Acute Leukemia Immunological Microenvironment with 3D Biology™ Technology - DEC 05, 2017 9:00 AM PST
Doug Hinerfeld, Ph.D., Principal Product Application Scientist, NanoString Technologies; Sergio Rutella, M.D., Ph.D., Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, Nottingham Trent University
Therapeutic strategies in patients with acute myeloid leukemia (AML) have remained relatively unchanged over the last 30 years. The development and delivery of new therapeutic strategies for high-risk AML, including immunotherapy, therefore remains a priority. Tumor phenotypes are dictated not only by the neoplastic cell component, but ...